A new trading day began on Friday, with Verve Therapeutics Inc (NASDAQ: VERV) stock price down -3.26% from the previous day of trading, before settling in for the closing price of $4.60. VERV’s price has ranged from $2.86 to $9.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -0.95%. With a float of $65.76 million, this company’s outstanding shares have now reached $88.80 million.
Let’s look at the performance matrix of the company that is accounted for 274 employees. In terms of profitability, gross margin is 36.09%, operating margin of -349.68%, and the pretax margin is -303.09%.
Verve Therapeutics Inc (VERV) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 26.23%, while institutional ownership is 73.84%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.40% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Here are Verve Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Verve Therapeutics Inc (NASDAQ: VERV) saw its 5-day average volume 3.05 million, a positive change from its year-to-date volume of 2.57 million. As of the previous 9 days, the stock’s Stochastic %D was 61.31%. Additionally, its Average True Range was 0.45.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 24.67%, which indicates a significant decrease from 47.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.42% in the past 14 days, which was lower than the 106.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.63, while its 200-day Moving Average is $5.66. Nevertheless, the first resistance level for the watch stands at $4.60 in the near term. At $4.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.88. If the price goes on to break the first support level at $4.31, it is likely to go to the next support level at $4.18. Assuming the price breaks the second support level, the third support level stands at $4.03.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
With a market capitalization of 396.69 million, the company has a total of 89,143K Shares Outstanding. Currently, annual sales are 32,330 K while annual income is -198,710 K. The company’s previous quarter sales were 32,980 K while its latest quarter income was -31,030 K.
